| Drug General Information |
| Drug ID |
D00XDG
|
| Former ID |
DNC006546
|
| Drug Name |
5-amino-2-phenyl-oxazole-4-carboxylic acid amide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H9N3O2
|
| Canonical SMILES |
C1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N
|
| InChI |
1S/C10H9N3O2/c11-8(14)7-9(12)15-10(13-7)6-4-2-1-3-5-6/h1-5H,12H2,(H2,11,14)
|
| InChIKey |
UPWLRKVVLBSIPK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Inhibitor of nuclear factor kappa B kinase beta subunit |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Chemokine signaling pathway
|
|
NF-kappa B signaling pathway
|
|
FoxO signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Insulin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Prostate cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
TCR signaling in naï
|
|
Canonical NF-kappaB pathway
|
|
TRAIL signaling pathway
|
|
TCR signaling in naï
|
|
FAS (CD95) signaling pathway
|
|
IL1-mediated signaling events
|
|
mTOR signaling pathway
|
|
TNF receptor signaling pathway
|
|
FoxO family signaling
|
|
p75(NTR)-mediated signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
Endogenous TLR signaling
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
Activation of NF-kappaB in B cells
|
|
NOD1/2 Signaling Pathway
|
|
RIP-mediated NFkB activation via ZBP1
|
|
p75NTR recruits signalling complexes
|
|
NF-kB is activated and signals survival
|
|
FCERI mediated NF-kB activation
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Interleukin-1 signaling
|
|
Regulation of TNFR1 signaling
|
|
TNFR1-induced NFkappaB signaling pathway
|
|
IKBKB deficiency causes SCID
|
|
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
|
|
IkBA variant leads to EDA-ID
|
|
CLEC7A (Dectin-1) signaling
|
|
MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
|
TRAF6 mediated NF-kB activation
|
|
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
|
|
IRAK1 recruits IKK complex
|
|
IKK complex recruitment mediated by RIP1
|
|
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Estrogen signaling pathway
|
|
TCR Signaling Pathway
|
|
Insulin Signaling
|
|
IL-4 Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
NLR Proteins
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
MyD88 cascade initiated on plasma membrane
|
|
Cardiac Hypertrophic Response
|
|
Cytosolic sensors of pathogen-associated DNA
|
|
MyD88 dependent cascade initiated on endosome
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Fc epsilon receptor (FCERI) signaling
|
|
MyD88-independent cascade
|
|
Signaling by the B Cell Receptor (BCR)
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
EBV LMP1 signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Apoptosis
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
BDNF signaling pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
IL17 signaling pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Signalling by NGF
|
|
IL-1 signaling pathway
|
|
TCR signaling
|
|
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
|
|
Interleukin-1 signaling
|
|
Apoptosis Modulation and Signaling
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Regulation of toll-like receptor signaling pathway
|
|
Osteopontin Signaling
|
|
NOD pathway
|
| References |
| REF 1 | J Med Chem. 2006 May 18;49(10):2898-908.Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. |
|---|
